v, Traumatic spinal cord injury occurs in two phases: biomechanical injury, followed by ischemia and reperfusion injury. Biomechanical injury to the spinal cord, preceded or followed by various pharmaceutical manipulations or interventions, has been studied, but the ischemia/reperfusion aspect of spinal cord injury isolated from the biomechanical injury has not been previously evaluated. In the current study, ischemia to the lumbar spinal cord was induced in albino rabbits via infrarenal aortic occlusion, and two interventions were analyzed: the use of U74006F (Tirilazad mesylate), a 21-aminosteroid, and cerebrospinal fluid (CSF) drainage. These treatment modalities were tested alone or in combination.
done to reverse direct mechanical injury during trauma. 29' 6~ In the usual blunt-trauma model of spinal cord injury, damage secondary to mechanical injury cannot readily be separated from damage secondary to delayed ischemic injury and probable reperfusion injury. In this experimental system, spinal cord injury can be studied in terms of spinal cord ischemia without the superimposed injury occurring from mechanical trauma. Intra-aortic balloon occlusion was used to study the ischemic component in isolation. The purpose of the study was to test the effect of two modalities, alone or combined, in improving the neurological outcome of ischemic spinal cord injury: 1) a free radical scavenger, 21-aminosteroid (Tirilazad mesylate*); and 2) cerebrospinal fluid (CSF) drainage.
Materials and Methods

Study Phases
Phase 1. Tirilazad was tested versus vehicle control in 10 rabbits each. A total of 40 minutes of infrarenal aortic occlusion was performed followed by strict evaluation of neurological outcome at 12, 24, 48, 72, and 96 hours after occlusion. The neurological outcome was scored according to the following scale: 0 = no movement; 1 = trace movement; 2 = sits with assistance; 3 = sits unassisted but cannot hop; 4 = weak hop; and 5 = normal hop. For some analyses, the animals' functional neurological outcome was graded as either paraplegic or nonparaplegic.
Phase 2. The rabbits were subdivided into five groups: 1) control animals with sham surgery; 2) animals that underwent CSF drainage alone; 3) animals that received Tirilazad alone; 4) animals that underwent Tirilazad treatment plus CSF drainage; and 5) control animals that underwent surgery with no aortic occlusion, but received Tirilazad alone. The functional outcome, CSF pressure, and calculated spinal cord perfusion pressure were analyzed, and the relationship between these parameters and the animals' functional neurological outcome was determined.
Experimental Design
Forty-six New Zealand albino rabbits were used in the two-phase study. The experimental setup is illustrated in Fig. 1 . Eight hours before occlusion, each animal received via intraperitoneal injection either 1.0 mg/kg of Tirilazad or an equivalent volume of the vehicle (0.5 N hydrochloride solution). The rabbits were then anesthetized with 40 mg/kg of ketamine and 10 mg/kg of xylazine administered intramuscularly. To rule out a possible protective effect of ketamine or xylazine, control animals subjected to an operation alone and animals that underwent operation and balloon occlusion but no other drug therapy were compared to animals that received CSF drainage alone, Tirilazad treatment alone, or CSF drainage and Tirilazad treatment combined. The rabbits were prepared and draped in a sterile fashion and placed under a halothane hood at 1.5% volume flow rates for maintenance of the anesthesia. A heating pad prevented hypothermia. The animals were allowed to ventilate spontaneously with no attempt to adjust the anesthesia to any particular blood gas level. Intravenous access was established via an ear vein, and antibiotic agents were given preoperatively.
Operative Technique
Bilateral inguinal incisions were made to isolate both femoral arteries. A No. 20 angiocatheter was placed in one artery to monitor distal aortic pressure, and a No. 3 French vascular catheter was introduced into the contralateral artery and directed approximately to the level of the inguinal ligament. Both catheters were transduced. A celiotomy was performed to isolate the aorta at the level of the left renal artery. Five minutes prior to balloon occlusion, each animal received intravenous hepafin plus either 1 mg/kg of Tirilazad or an equivalent volume of vehicle. Two additional doses of test drug or vehicle (1 mg/kg) were then given intravenously at 10 and 20 minutes after balloon occlusion.
To occlude the aorta, a No. 3 French catheter was advanced proximally within the infrarenal aorta 2 cm above the left renal artery. A vascular loop was placed via the celiotomy approximately 1 cm inferior to the left renal artery. The loop was then secured tightly with a hemostat and the celiotomy was closed. Since in the lumbar spine the cord is fed by radicular arteries branching from the aorta, such an occlusion would induce ischemia below the level of occlusion. Body temperature, heart rate, and proximal and distal aortic pressures were recorded throughout the 40-minute occlusion period.
After balloon occlusion, functional neurological out-come alone was tested in the Phase 1 animals. In Phase 2, additional experiments were employed, in particular using CSF drainage to decrease CSF pressure. To alter and measure CSF pressure, the rabbits were turned with their shoulders upright, exposing the posterior aspect of the neck and the base of the skull. Through a posterior midline incision, a No. 24 angiocatheter was placed into the cisterna magna. Correct placement was checked by observing the waveform of the CSF pressure, in particular looking for respiratory and cardiovascular variation. Any animal a with bloody spinal tap was excluded from the study because intrathecal blood has a significant effect on measured CSF pressure. For the animals in which CSF was drained, the angiocatheter that had been placed in the cisterna magna was left open to atmospheric pressure; in addition, the pressure was transduced on a continuous basis. The perfusion pressure was calculated by finding the difference between CSF pressure and mean arterial blood pressure (MABP) measured distal to the occlusion. The MABP gives a rough approximation of the arterial pressure below the level of the occlusion, and can be determined from a separate catheter placed in the contralateral artery to the balloon-containing catheter, as mentioned previously. The CSF pressure was measured as described above at the same level in the supine animal as the MABP. The difference between MABP and CSF pressure yields a perfusion pressure, and this calculated perfusion pressure was used as a relative measurement to approximate perfusion pressure at the spinal cord. The amount of CSF drained was not kept at a constant but rather was allowed to equilibrate with the atmospheric pressure, the amount usually being only a few cubic centimeters. The pressure was therefore zeroed, in a sense, at the start of the experiment in the CSF drainage groups and the volume drained was not directly measured.
In both Phase 1 and Phase 2, the hemostatic vessel loop was removed after 40 minutes and the No. 3 French catheter was then withdrawn. Each animal received 1.0 mg/kg of Tirilazad or vehicle intravenously at 2 hours after occlusion and then every 6 hours until a total of 38 hours had passed since the occlusion. Neurological assessment was performed on all animals at 12, 24, 48, 72, and 96 hours after occlusion.
Pathological Analysis
Pathological evaluation was carried out in 14 spinal cords. Entire spinal columns were removed immediately after the animals had been sacrificed, and total laminectomies were performed to allow optimum penetration of the fixative to the spinal cord. A 10% phosphate-buffered formalin solution was used as a fixative for at least 10 days. The spinal cords with nerve roots including dorsal root ganglia were removed from the spinal columns and representative specimens were obtained from the thoracic, lumbar, and sacral spinal cords, including the cauda equina. Paraffin-embedded specimens were processed in the standard fashion and stained with hematoxylin and eosin (H & E). Specimens obtained from the upper thoracic cord were treated as P. C. Francel, et al. Pathological analysis included extent of neuronal damage, intensity and character of the inflammatory response, changes in blood vessels, and changes in white matter. For the purpose of analysis, a simplified scale of neuronal damage was introduced: Grade 0, extensive generalized neuronal loss; Grade 1, extensive neuronal loss with focal changes at different levels; Grade 2, focal neuronal loss; Grade 3, eosinophilia and/or pyknosis; and Grade 4, normal.
Results
Effect of Tirilazad Administration
The results of Phase 1 are illustrated in Fig. 2 . In the animals receiving Tirilazad, a significant percentage were nonparaplegic and, when scored as described above, showed far better neurological function than vehicle-treated control animals. All of these animals were tested unanesthetized during evaluation at 96 hours after the 40-minute occlusion. Evaluations were not performed past the 96-hour period in this experiment. Figure 3 summarizes the functional neurological outcome observed at both 48 hours and 96 hours postocclusion in the Phase 2 animals. Neurological outcome is expressed as a percent paraplegia rate. Tirilazad administration alone showed no deleterious neurological effects on the animals, whether or not they underwent occlusion.
Tirilazad Administration Plus CSF Drainage
To evaluate one possible mechanism of protection produced by the test drug, CSF pressure and perfusion pressure (measured just prior to removal of the hempstatic vessel loop 40 minutes after occlusion) were analyzed (Fig. 4) . All treated animals showed a significant decrease in CSF pressure compared to control animals, which translated into an increase in calculated perfusion pressure (Table 1) . Tirilazad administration and CSF drainage together produced the largest drop in CSF pressure, resulting in an even larger increase in perfusion pressure. To more fully analyze the beneficial effects of Tirilazad treatment and/or CSF drainage, the functional neurological outcome relative to CSF pressure and calculated perfusion pressure of all experimental and control animals was then evaluated (Table 2 ). These resu]ts enabled us to correlate a specific change in CSF pressure and calculated perfusion pressure with a functional neurological outcome (Fig. 5) . Comparisons relative to paraplegia versus nonparaplegia were made for all groups of experimental animals, not just the treatment groups or the control group. The group of nonparaplegic animals showed a drop in CSF pressure and a resultant increase in the calculated perfusion pressure; the paraplegic animals did not show the same magnitude of change.
Pathological Findings
Fourteen spinal cords were evaluated microscopically. In this group of rabbits, three animals had under- gone sham operation, three had received vehicle only (controls), three had received Tirilazad only, three had undergone CSF drainage only, and two animals had been treated with Tirilazad administration and CSF drainage. The animals that underwent sham operation remained neurologically intact (neurological outcome score 5). Among the three animals in the occlusion control group, the average final outcome score was 2.5. The animals in groups with either Tirilazad alone or CSF drainage alone had fairly good preservation of function, with an average final outcome score of 3.7 in each group. A consistently better result was achieved in animals that received both Tirilazad and CSF drainage, with an average end result of 4.
These clinical results correlated well with changes observed in the pathological specimens (Fig. 6) . The most severe microscopic changes were observed in the control group animals and were characterized by extensive and diffuse neuronal loss, white matter edema, capillary endothelial swelling, and proliferation (Fig.  6A) . The spinal cords were normal in the sham group (Fig. 6B) . The spinal cords in the Tirilazad group without CSF drainage differed dramatically from those in the vehicle control group: in the former, only occasional focal damage to the gray matter and more limited mononuclear inflammatory cell reaction was seen (Fig.  6C ). In the animals that underwent CSF drainage, only eosinophilia and pyknosis of some motor neurons were found (Fig. 6D) ; one area of focal neuronal loss was observed in one animal. The Tirilazad treatment plus CSF drainage group showed the best results, with either normal or near-normal cords. Additional important information in this subgroup of 14 animals was obtained from continuous CSF pressure monitoring. The animals treated with either Tirilazad therapy or CSF drainage had markedly lower CSF pressures than control group animals, with mean endpoint pressures of 4.7, 1.7, and 1 1 tort, respectively (standard error of the mean < 10%).
Discussion
The results of this study suggest that Tirilazad administration and/or CSF drainage lower CSF pressure and improve the perfusion pressure to the spinal cord. These changes correlate with an improvement in functional neurological outcome. 3'4' 17.64.77 This correlation was studied in an experimental model that analyzed the ischemic component of injury in isolation from mechanical injury to the spinal cord. This is important for it is thought that in the ischemic and possibly the reperfusion phases of spinal cord injury, there is ongoing biochemical and metabolic destruction of the spinal cord and that frequently this secondary injury may be the foremost component contributing to the final functional neurological outcome. In addition, ischemia may be the only phase of injury at present in which medical intervention might prevent further spinal cord damage.
Recent research has indicated that much of the ischemic and reperfusion injury to central nervous system (CNS) elements is secondary to the production of free radicals that alter lipid membranes, inducing lipid peroxidation with further destruction of cells and ultimately cell death. 4"6"13"~8"~-~176 This alteration occurs in the neural, vascular, and supporting cells of the CNS. Indeed, Demopoulos, et aL, 23 theorized that both regional ischemia and acute spinal cord injury are mediated via the production of free radicals that attack the cell membrane lipids in the traumatized zone.
In models that analyze blunt spinal cord injury, it has been noted that severe blunt trauma results in a progressive decrease of spinal cord blood flow in the injured segment. 43 Initially, there is actually a short phase of hyperemia secondary to the loss of autoregulation in the microvasculature. This loss appears to peak at about 10 minutes after injury and normalize at approximately 30 minutes after injury. Normal spinal cord blood flow is approximately 15 ml/100 gm/min, with a lower limit of about 10 ml/100 gm/min. Severe blunt trauma will cause spinal cord blood flow to decrease to levels that induce irreversible damage. It has been previously shown that this decrease in spinal cord blood flow can be reversed by administering TirilazadJ 3
Hall and several others z~'3~'39-54'56~~176 have proposed a sequence of events that may occur during spinal cord injury and ischemia. These researchers noted that blunt spinal cord injury results in hemorrhage at the traumatized zone and also in a significant influx of calcium into the traumatized cells. The calcium influx activates other mechanisms, including the activation of various phospholipases and the subsequent release of arachidonic acid as well as increased prostaglandin synthetase activity.122728'3~
More importantly, the initial cascade of damage induces the production of free radicals and lipid per- oxidation products that activate phospholipases, resulting in the further release of arachidonic acid. The arachidonic acid is then metabolized via prostaglandin synthetase-catalyzed reactions, producing various arachidonic acid metabolites. Many of these metabolites, including thromboxane E2 and prostaglandin F_~,, are potent mediators of ischemia.
Iron released from hemoglobin present in damaged red blood cells at the site of trauma is a very potent catalyst for free radical production and lipid peroxidation. u'~6 The arachidonic acid metabolites promote further ischemia in the gray matter, and this gray matter ischemia produces fairly significant lactic acidosis intracellularly and free radical generation, which then produces further lipid peroxidation. The oxygen-containing free radicals and lipid peroxidation products appear to be the central mediators of the ischemic damage to the traumatized tissues. Unfortunately, the lipid peroxidation products and free radicals promote further release of arachidonic acid and further production of the ischemia-promoting arachidonic acid metabolites.
These metabolites also promote spread of ischemia from the gray matter into the white matter, producing demyelination and axonal damage that result in permanent neurological deficits.
Mechanisms of Action of Tirilazad
Tirilazad has been shown to be a very potent scavenger of free radicals and in particular an extremely potent inhibitor of lipid peroxidation. 3"12"13K84~ 47,50.52.54.55~59,60.64 It is very effective in the reactions catalyzed by iron. Tirilazad also appears to decrease the amount of arachidonic acid released at the trauma site. This decrease may be secondary to its inhibition of the positive feedback pathway mentioned previously or may be due to a separate second mechanism. The antioxidant effect is not related to any glucocorticoid activity of this compound. Tirilazad does not have any effect on the hypothalamic-pituitary-adrenal axis and does not appear to act via the steroid receptor.
In a cat model of acute subarachnoid hemorrhage, Tirilazad treatment has shown a blunting of the rise in intracranial pressure (ICP), suggesting that one mechanism providing CNS protection in spinal cord injury might be the effect of Tirilazad on CSF pressure. 55 If Tirilazad administration also blunted the rise in ICP by lowering CSF pressure and thereby improving peffusion pressure, we thought that the drug may translate this improvement in perfusion to greater functional outcome.
The ability of this antioxidant, the so-called "lazeroid compound," to decrease CSF pressure has not been analyzed. When CSF pressure is lowered, the intraspinal pressure is significantly reduced, which in turn reduces ischemic damage by improving the perfusion pressure to the neural and supporting tissue. 356~ '62"87 Results showing that CSF drainage actually induced an improvement in neurological outcome and in perfusion pressure to the injured spinal cord illustrated the possible importance of the CSF pressure effect. The combination of CSF drainage and Tirilazad treatment appeared to further reduce the CSF pressure and promote an even larger increase in the perfusion pressure, resulting in an improvement in neurological outcome.
Tirilazad Treatment and CSF Drainage
There was a remarkable difference in the general functional outcome and in rates of paraplegia and nonparaplegia in the animals studied. The ability of Tirilazad administration and/or CSF drainage to produce improved functional neurological outcome was quite significant, with many more animals in the experimental groups showing improvement in their functional capabilities and a much larger percentage being nonparaplegic.
The fact that both CSF drainage and Tifilazad administration showed improvement in this particular model of ischemic spinal cord injury suggests that such treatment would be useful in spinal cord injury secondary to multiple causes and not just in trauma per se. For example, Tirilazad treatment and/or CSF drainage might be used to prevent spinal cord ischemia during some component of planned surgery such as lumbar or cervical decompression in patients with lumbar or cervical stenosis. The procedure may be useful during intradural and especially intramedullary spinal cord procedures. Indeed the spinal cord protection provided by these agents may be initiated prior to the insult to the spinal cord. Using such an agent prior to the actual injury period is extremely useful because much of the ischemic and reperfusion injury to the spinal cord actually occurs soon after the initial biomechanical injury.J ~.~2 Non-neurosurgical applications include using Tirilazad during the repair of abdominal aortic aneurysms or in any procedure in which blood flow in the aorta or other smaller vessels supplying the spinal cord may be temporarily reduced or stopped. 7"9' 1~ 71, 72,74,82,84.88 
Pathology and Tirilazad Administration Plus CSF Drainage
Our initial investigations showed that both the functional and the physiological improvement produced by P. C. Francel, et al.
these two interventions resulted in significant alterations in the pathological specimen. When the animals underwent infrarenal aortic balloon occlusion, marked necrosis of the spinal cord was noted throughout both the gray and white matter. All three experimental treatments (Tirilazad alone, CSF drainage alone, and Tirilazad plus CSF drainage) diminished the pathological changes. In particular, the spinal cords in animals receiving the combined treatment showed a normal or near-normal appearance with only occasional pyknosis of neurons and occasional areas of eosinophilia noted on H & E-stained specimens. A marked improvement was noted with either of the treatments used alone, although occasionally pathological specimens showed some areas of focal necrosis.
Conclusions
Using a model that induces spinal cord ischemia by occluding the intrarenal aorta allowed evaluation of several possible protective interventions. This model effectively induces ischemic injury followed by reperfusion injury without a biomechanical insult to the spinal cord, thereby enabling the study of ischemia/ reperfusion in relative isolation from biomechanical injury. We analyzed the possible protective action of Tirilazad (a free radical scavenger, antioxidant, and lipid peroxidation inhibitor) and CSF drainage in inhibiting the damage mediated during spinal cord ischemia. Both Tirilazad administration and CSF drainage provided a significant degree of protection against neurological deficit in the spinal cord. Cerebrospinal fluid pressure rose during ischemia in untreated animals, while both Tirilazad treatment and CSF drainage reversed this rise and lowered the CSF pressure. It is likely that Tirilazad administration not only inhibits damage from ischemia by blocking the deleterious effects of free radicals and lipid peroxide metabolites, but it may also provide protection by decreasing CSF pressure. This decrease in CSF pressure results in improved perfusion pressure to the spinal cord. How spinal cord injury actually induces the decrease in intraspinal perfusion pressure has not been fully elucidated, but it appears that the ischemia-and reperfusion-dependent component of this decrease in intraspinal perfusion pressure can be significantly reversed using Tirilazad treatment or CSF drainage. We believe that Tirilazad administration and/or CSF drainage may be useful in the treatment of patients with multiple types of spinal cord injuries, including both traumatic and isolated ischemia/reperfusion injury. 
